Teva- Pharmaceutical Industries Ltd
NYSE: TEVA
$16.57
-$0.02 (-0.1%)
Closing Price on November 27, 2024
TEVA Articles
One key stock to watch next week is Pfizer Inc. (NYSE: PFE). While it has been in the land of the boring forever, watchers are looking to see if it will put in a rival bid over the $4.6 Billion...
Published:
Here are some of the top stories today that affecting key drug and biotech stocks: GlaxoSmithKline (NYSE: GSK) reorganized its corporate structure, increasing focus on emerging markets such as China,...
Published:
Bentley Pharmaceuticals Inc. (NYSE: BNT) will be purchased by Teva Pharmaceutical Industries (NASDAQ: TEVA) for $360 million. Bentley shareholders will receive $15 per share and an undisclosed amount...
Published:
Last Updated:
Below are the top 10 analyst calls we are focusing on this morning: Boeing (NYSE: BA) raised to Overweight at Morgan Stanley. Omniture (NASDAQ: OMTR) raised to Buy at Jefferies. PepsiAmericas (NYSE:...
Published:
Teva Pharmaceutical (NASDAQ: TEVA – News) has some pretty loft goals for itself at its Investor Day presentation. If you trust the company’s history and its pipeline of candidates under trials...
Published:
Teva Pharmaceuticals (NASDAQ: TEVA) posted earnings at $0.69 EPS on revenues of $2.58 Billion; First Call had consensus at $0.66 EPS on $2.48 Billion in revenues. There are some big numbers ahead for...
Published:
These are not the only analyst impact calls, but these are the top research notes that a673b.bigscoots-temp.com is focusing on: Adobe Systems (ADBE) raised to Buy at Deutsche Bank. Cirrus Logic (CRUS) raised to...
Published:
Last Updated:
Bear Stearns Upgrades PCAR to outperform. Think Equity downgrades YHOO to accumulate. LXK cuts guidance for Q2. TEVA upgraded to outperform at Bear Strearns. ESV downgraded to underperform at Credit...
Published:
AGN started as Buy at Jefferies.AW started as Outperform at Credit Suisse.BAY started as Overweight at JPMorgan.CACH cut to Neutral at Merriman Curhan Ford.CIEN started as Outperform at Piper...
Published:
Mylan Labs (MYL-NYSE) is seeing its shares take a beating because it is acquiring Merck KGaA’s generic unit and Mylan is the acquirer in what is a very leveraged buyout. It isn’t just the fact...
Published: